Company intelligence / Profile preview

Phospholipid GmbH

Cologne, North Rhine-Westphalia, Germany

Ownership: Private
Development stage: Other

Overview

The company is focused on developing phospholipid-based reformulations of existing drugs (Line Extensions) to improve safety and efficacy. Their lead clinical program, a phospholipid-based ibuprofen formulation, is in Phase 1 clinical testing and has demonstrated improved gastrointestinal safety in preclinical models.

Therapeutic areas: ImmunologyNeurologyGastroenterologyOncologyOphthalmology
Modalities: Small moleculeLiposomeNanoparticleLipid nanoparticle delivery therapy
Industry: Biotech

Partnerships

LipoidPhospholipid Research Center Heidelberg

Beyond the preview

Go deeper on Phospholipid GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phospholipid GmbH.

Explore the full profile